Description: The Inflation Reduction Act (IRA) introduced major changes to the Part D program. This session will unpack the impact of IRA's benefit redesign in 2025 premiums, costs, and beneficiary choices, and the implication of drug price negotiation in 2026. We will discuss how Part D plans are adapting to these changes, lessons learned from the 2025 bids, and what we can expect in 2026 after the price negotiation of the top ten Part D drugs.

Description: Discuss the dramatically changing provider landscape, as well as the innovative solutions being leveraged by providers to address the intriguing opportunities and complex challenges. Among the questions to be answered are the following: How can providers capitalize on employers’ desire to contract directly with local providers? What's the path for providers to develop employer stop-loss (ESL) capabilities to maximize network value/impact? Can providers create a risk portfolio including ESL for local employers, their own employee plan, and other delegated risk arrangements such as Medicare Advantage? How can captive insurers support a provider's risk strategy?

Description: Session 5F: Next Evolution of Preventive Care - Driving Better Outcomes!

Description: Session 2A: Navigating Medicaid Single Preferred Drug Lists (PDLs) - A Deep Dive

Description: Discussion of recent developments in the taxation of noncoordinated benefits such as fixed indemnity, hospital indemnity, and specified disease insurance policies. Developments include a recent Chief Counsel Advice Memorandum and proposed triagency rulemaking that would impact non coordinated benefits.

Description: The article discusses ACLI's comment letters submitted to Treasury and the IRS in response to the proposed regulations on the Corporate Alternative Minimum Tax and Ranking Member Ron Wyden (D-OR)'s discussion draft of the Protecting Proper Life Insurance From Abuse Act, that would impact the taxation of some to private placement life insurance.

Description: This article provides a high-level description of how the One Big Beautiful Bill passed enacted on July 4, 2025 specifically affects life insurers. Primarily in this article, ACLI reflects on its 18-year collaboration with the Society of Actuaries through the Taxing Times publication, highlighting key tax legislation impacts and ongoing advocacy for the life insurance industry. This final column acknowledges past achievements and emphasizes continued commitment to industry representation amid evolving challenges.

Description: The big event of 2023 is the launch of multiple Humira biosimilars, which began in January with the arrival of Amgen’s Amjevita on the market. The launch of Amjevita kicks off the process of changing the specialty drug marketplace in the United States. The expectation of the full impact of this big event is very hopeful, but there is still uncertainty several months after its beginning. Humira is the highest-selling drug in the world and has been since 2013 (Figure 1)—except for when COVID-19 projects temporarily surpassed it. The world is eagerly awaiting the launch of multiple biosimilar drugs to compete with Humira and hopefully bring more competitive pricing to the benefit of payers and patients everywhere.

Description: This report explores AI bias in insurance and health data, highlighting the ethical role of actuaries and offering cross-disciplinary guidance for fairer decision-making systems.

Description: Metadata for entire issue